Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

55.68 +0.07 (+0.13%)
Streaming Delayed Price Updated: 2:47 PM EDT, Jul 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Present at Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 807 companies reached new 52-week lows. 
Via Benzinga
News headline image
Analyst Ratings for Veracyte ↗
Within the last quarter, Veracyte (NASDAQ:VCYT) has observed the following analyst ratings: 
Via Benzinga
News headline image
Recap: Veracyte Q4 Earnings ↗
Veracyte (NASDAQ:VCYT) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte... 
Via Benzinga
News headline image
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Earnings Perspective: Return On Capital Employed ↗
Veracyte (NASDAQ:VCYT) brought in sales totaling $67.78 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 37.36%, resulting in a loss of $14.46 million. 
Via Benzinga
News headline image
Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 28, 2022 ↗
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
News headline image
Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
From Veracyte
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
During Thursday, 351 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
From Veracyte, Inc.
Via Business Wire
News headline image
Recap: Veracyte Q1 Earnings ↗
Veracyte (NASDAQ:VCYT) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte beat estimated earnings by... 
Via Benzinga
News headline image
Veracyte Announces First Quarter 2022 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Earnings Scheduled For May 3, 2022 ↗
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter. 
Via Benzinga
News headline image
Preview: Veracyte's Earnings ↗
Veracyte (NASDAQ:VCYT) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Veracyte will... 
Via Benzinga
News headline image
Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022
From Veracyte, Inc.
Via Business Wire
News headline image
10 Biggest Price Target Changes For Tuesday ↗
Keybanc cut the price target on Workday, Inc. (NASDAQ: WDAY) from $345 to $312. Workday shares rose 5.7% to $242.00 in pre-market trading. 
Via Benzinga
News headline image
Veracyte Appoints Annie McGuire as General Counsel
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Appoints Jonathan Wygant as Chief Accounting Officer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy In Men with Intermediate-Risk Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in 11th Annual SVB Leerink Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer
From Veracyte, Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.